Report shines light on the current state of the Phase II/III clinical trial market and its anticipated direction into 2020.
We can’t read the future, but we can certainly help you make smart decisions heading into it. Industry Standard Research (ISR) has come out with a new report that shines a light on both the current state of the Phase II/III clinical trial market as well as its anticipated direction into 2020. “Phase II/III Study Trends and Market Outlook (2016-2020)” contains analysis of emerging trends, Phase II/III spend, and outsourcing behaviors that are expected to shape this realm in the coming years. Both sponsors and service providers will gain information they can utilize to situate themselves effectively for the expected twists and turns in a future market. One important take-away from this report concerns the increasing relevance of the developing world in the Phase II/III sphere. Decision-makers foresee a notable shift of Phase II/III studies from developed markets into emerging market regions in the coming years.
Increases are also anticipated for emerging market patient recruitment, of which further analysis can be found in the report. These findings indicate that the future of the Phase II/III market will likely be marked by a change in regional demographics and terrains. The expected trend will call for a strong understanding of clinical spaces across global territories, and an increased cultural competence moving forward in Phase II/III endeavors. Altogether, the findings in this report paint a robust picture of foreseen market behavior for industry decision-makers. “Phase II/III Study Trends and Market Outlook (2016-2020)” provides in-depth accounts from 112 high-level pharmaceutical and biotech decision-makers responsible for Phase II/III drug development activities within their companies. For sponsors, use this report to know what your industry peers expect for their business direction and study investments, and understand how your company’s strategy compares to that of your competition. For service providers, the report will inform you of the capabilities and services expected to be sought in a future Phase II/III market. Move forward knowing where to bolster your capacity. So stay ahead of the game and make informed decisions for your business’s future. More information on ISR’s “Phase II/III Study Trends and Market Outlook (2016-2020)” can be found at: https://www.isrreports.com/reports/phase-iiiii-study-trends-and-market-outlook/
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Phase III Trials Show Long-Term Efficacy of Cobenfy Treating Schizophrenia
November 1st 2024Cobenfy (xanomeline and trospium chloride) demonstrated sustained long-term efficacy, safety, and tolerability over 52 weeks in Phase III trials for adult schizophrenia patients, showing significant symptom improvement and quality of life benefits with minimal adverse effects.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
WCG Randomized 1,600 Participants for RSV Vaccine Trial
October 31st 2024A top 5 sponsor turned to WCG to recruit expecting mothers for its Phase III RSV vaccine trial. WCG support covered multiple countries and contributed almost one third of overall randomizations in the supported countries, bringing the study in ahead of schedule despite delays due to COVID-19 impacts on RSV seasonality. The sponsor met study timeline past enrollment by continuing to work with WCG’s retention support.